Zolinza (vorinostat, MK0683)
| Brand Name: | Zolinza |
| Generic Name: | vorinostat |
| Code Name: | MK0683 |
| Company: | Merck Pharmaceuticals |
| FDA Clinical Phase: | 3 |
Description:
Zolinza, which is an approved drug for cutaneous T-cell lymphoma, is also being studied in combination with Velcade (bortezomib) for treatment of multiple myeloma. Zolinza is a histone deacetylase (HDAC) inhibitor, which modifies the way that cancer cell DNA is converted into protein. HDAC controls DNA unfolding in the first step of protein production, and drugs that inhibit HDAC, like Zolinza, increase the production of protein. HDAC inhibitors are used in cancer treatment to increase the production of proteins that slow cell division, repair DNA mistakes, and control cell death. Researchers hope that this should help the body prevent cells from multiplying out of control and becoming cancerous.
Clinical Trials:
Currently, there are several open clinical studies involving Zolinza.
Official Web site for Zolinza: http://www.zolinza.com/
Related Articles:
- Anti-Cancer Drug Zolinza Shows Potential In Myeloma
- Phase 3 Zolinza-Velcade Trial Opening Soon
- Phase 1 Clinical Trial Of CX-4945 Begins In Cancer Patients
- Zolinza-Velcade Combination May Be Effective In Relapsed/Refractory Myeloma
- Phase 1 Clinical Trial Studies Velcade And Zolinza In Myeloma Patients
Leave a comment